Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 8/16/2018 |
| Start Date: | December 2013 |
| End Date: | April 2017 |
The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of
patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to
the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission
(CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell
transplantation (SCT).
patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to
the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission
(CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell
transplantation (SCT).
Inclusion Criteria:
1. Age greater than or equal to 18 years
2. Able to give informed consent
3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2
Exclusion criteria:
1. Has already had a bone marrow biopsy and aspirate to assess remission status after
induction therapy
2. Any debilitating medical or psychiatric illness that would preclude ability to give
informed consent or receive optimal treatment and follow-up
3. Pregnancy: Women of childbearing potential who are β- HCG+
We found this trial at
1
site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
